Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Our goal is to develop ways of accurately measuring neurological disorders such as Parkinson’s disease and Progressive Supranuclear Palsy.

Our approach

Most medical conditions can be rapidly and objectively quantified using standard equipment. However, the 'gold standard' measure of many brain diseases is still a clinical rating scale, a system of points assigned by an observer based on their impression of the person's condition. Such scales show significant inter-observer variability, and they are also nonlinear, limiting the statistical analyses that can be applied to them.

Our approach is to precisely measure abnormalities of movement and its control using neuropshysiological biomarkers. Eye movements have proved to be a particularly rich source of information because they can be evaluated quickly and reliably with equipment that is portable and therefore usable in a clinic setting. We are also developing methods of measurement using both manual and cognitive tests, and have shown that these can be sensitive enough to detect dysfunction in Parkinson's disease even in its very early stages.

Research studies

Read about our Oxford QUantification In Parkinsonism study (OxQUIP).